Skip to main content

Table 2 Number of individuals with each symptom and no symptoms at 3 months, 6 months and long term follow-up (6 years) by randomisation group.

From: Long term follow-up of a randomised controlled trial of services for urinary symptoms

   Intervention Standard care Difference (95% Cl; P value)
   Total
responders
Individuals with symptoms/event (%) Total responders Individuals with symptoms/event (%)  
Improvement 3-months 2378 1417 (60%) 584 281 (48%) 11% (7 to 16; P = < 0.001)
  6 months 2201 1369 (62%) 536 277 (52%) 11% (6 to 15 P < 0.001)
  Long term follow-up 2045 1530(72%) 567 380 (67%) 5% (0.6 to 9; P = 0.02)
No symptoms (cure) 3-months 2378 591 (25%) 584 88 (15%) 10% (6% to 13%; p < 0.001)
  6 months 2201 624 (28%) 536 104 (19%) 9% (5% to 13%; p < 0.001)
  Long term follow-up 2069 643 (31%) 571 156 (27%) 4% (-0.4 to 8; P = 0.08)
Leakage
(several times per month or more)
Baseline 2958 2392 (82%) 788 618 (79%)  
  3 months 2483 1567 (63%) 612 428 (70%) -7% (-11% to -3%; p = 0.002)
  6 months 2235 1362 (61%) 546 356 (65%) -4% (-9% to 0%; p = 0.066)
  Long term follow-up 2093 1166 (56%) 580 334 (58%) -2% (-6 to 3; P = 0.4)
Frequency
(hourly or more)
Baseline   1563 (53%)   376 (48%)  
  3 months 2428 723 (30%) 598 219 (37%) -7% (-11% to -2%; p = 0.001)
  6 months 2231 539 (24%) 545 182 (33%) -9% (-14% to -5%; p < 0.001)
  Long term follow-up 2098 290 (14%) 576 85 (15%) -1% (-4 to 2; P = 0.6)
Urgency
(very strong or overwhelming)
Baseline   1927 (65%)   529 (67%)  
  3 months 2503 819 (33%) 618 248 (40%) -7% (-12% to -3%; p = 0.001)
  6 months 2236 682 (31%) 546 228 (42%) -11% (-16% to -7%; p < 0.001)
  Long term follow-up 2108 482 (23%) 583 153 (26%) -3% (-7% to 0.6%;p = 0.09)
Nocturia
(3 times per night or more)
Baseline   1070 (36%)   285 (36%)  
  3 months 2502 497 (20%) 617 164 (27%) -7% (-11% to -3%; p < 0.001)
  6 months 2236 420 (19%) 547 133 (24%) -6% (-9% to -2%; p = 0.004)
  Long term follow-up 2106 437 (21%) 585 135 (23%) -2% (-6 to 2; P = 0.2)